The success of specialized drugs to inhibit blood supply to tumors – so-called angiogenesis inhibitors – is compromised by the fact that these drugs do not effectively penetrate the tumor tissue and so do not reach the smallest blood vessels in the tumor, a new study has shown for the first time.